The U.S. healthcare industry is warning that the COVID-19 pandemic may threaten supplies of the medical radioisotope molybdenum-99, whose decay product, technetium-99m, is considered the workhorse isotope in nuclear medicine for diagnostic imaging. The online magazine Radiology Business recently reported that the American Society of Nuclear Cardiology (ASNC) alerted its members on April 1 that it is monitoring supply shortages of Mo-99 “more closely than ever” during the pandemic.

The Nuclear Regulatory Commission on March 24 relicensed the only uranium conversion plant in the United States, Honeywell International’s Metropolis Works.

Metropolis Works can now operate until March 24, 2060, potentially logging operations for over a century. Built in 1958 to produce uranium hexafluoride (UF6) for the U.S. government, Metropolis Works began selling UF6 on the commercial market in 1968.

The United States is pursuing the objective to land humans more than 100 million miles away on Mars, and nuclear power has the potential to be a key technology in getting to the Red Planet and providing power while there. Specifically, nuclear thermal propulsion (NTP) is a promising approach that could enable astronauts to travel from Earth’s orbit to Mars and back in a fraction of the time, and with greater safety, than is available with other options.